Prostate Cancer - Results from #940

REVIEW UroToday

Information on pros and cons of prostate-specific antigen testing to men prior to blood draw: A study from the National Prostate Cancer Register (NPCR) of Sweden, "Beyond the Abstract," by Jon Fridriksson, MD and Pär Stattin, MD, PhD February 1, 2013

Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis, "Beyond the Abstract," by Jay P. Ciezki, MD February 1, 2013

Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer, "Beyond the Abstract," by Zheng-Rong Lu, PhD, et al January 31, 2013

Measures of combined antioxidant and pro-oxidant exposures and risk of overall and advanced stage prostate cancer, "Beyond the Abstract," by Milan Geybels, PhD student January 30, 2013

Histopathologic features of atypical glands on prostate biopsy: Nucleolar size is a predictor of subsequent detection of prostatic adenocarcinoma, "Beyond the Abstract," by Sriram Venigalla, BS and Hiroshi Miyamoto, MD, PhD January 29, 2013

Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer: Matched-pair analysis, "Beyond the Abstract," by Michael Pinkawa, MD January 29, 2013

Prevalence and predictors of selenium and vitamin E supplementation in a urology population, "Beyond the Abstract," by Jennifer A. Locke, PhD January 25, 2013

Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1, "Beyond the Abstract," by Meena Jaggi, PhD, et al. January 25, 2013

Extended pelvic lymph node dissection including internal iliac packet should be performed during robot-assisted laparoscopic radical prostatectomy for high-risk prostate cancer, "Beyond the Abstract," by Koon Ho Rha, MD, PhD and Sey Kiat Lim January 25, 2013

A calculator for prostate cancer risk 4 years after an initially negative screen: Findings from ERSPC Rotterdam, "Beyond the Abstract," by Xiaoye Zhu, MD and Monique J. Roobol, PhD, MSc January 24, 2013

Testing the feasibility, acceptability and effectiveness of a 'decision navigation' intervention for early stage prostate cancer patients in Scotland - a randomised controlled trial, "Beyond the Abstract," by Belinda Hacking, MA, DClinPsychol, et al January 23, 2013

Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM), "Beyond the Abstract," by Andrea L. Russo, MD January 17, 2013

Effect of body mass index on intrafraction prostate displacement monitored by real-time electromagnetic tracking, "Beyond the Abstract," by Wayne M. Butler, PhD and Gregory S. Merrick, MD January 16, 2013

Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer, "Beyond the Abstract," by Ekaterina Olkhov-Mitsel and Bharati Bapat January 16, 2013

Serum Index Test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy, "Beyond the Abstract," by Massimo Lazzeri, MD, PhD and Giorgio Guazzoni, MD January 11, 2013

Kilovoltage intrafraction monitoring for prostate intensity modulated arc therapy: First clinical results, "Beyond the Abstract," by Paul Keall, PhD January 10, 2013

Intraductal carcinoma of the prostate: Precursor or aggressive phenotype of prostate cancer? "Beyond the Abstract," by Helmut Bonkhoff, MD January 8, 2013

Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy, "Beyond the Abstract," by Claude C. Schulman MD, PhD, et al January 7, 2013

Post-docetaxel therapy in castration resistant prostate cancer - the forest is growing in the desert, "Beyond the Abstract," by Amelia Altavilla, MD and Roberto Iacovelli, MD January 2, 2013

Treatment outcomes in non-metastatic prostate cancer patients with ultra-high prostate-specific antigen, "Beyond the Abstract," Patricia Tai, MB January 2, 2013

Page 48 of 57